Matthieu Arsicot

Matthieu Arsicot

Auto-generated profile, based on publicly available information

Matthieu Arsicot

Edouard Herriot Hospital, Department of Vascular surgery, Hospices Civils de Lyon, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
NSNellie Della Schiava
Nellie Della Schiava
MAMatthieu Arsicot
Matthieu Arsicot
TBTarek Boudjelit
Tarek Boudjelit
PFPatrick Feugier
Patrick Feugier
PLPatrick Lermusiaux
Patrick Lermusiaux
AMAntoine Millon
Antoine Millon

14 February 2022 in Trials
Verified
Journal Article
Open access
PDF file
MMMathilde Mura
Mathilde Mura
EREmeraude Rivoire
Emeraude Rivoire
LDLeila Dehina-Khenniche
Leila Dehina-Khenniche
MWMichèle Weiss-Gayet
Michèle Weiss-Gayet
BCBénédicte Chazaud
Bénédicte Chazaud
VPVincent Pialoux
Vincent Pialoux
Background: Carotid atherosclerotic plaques remain silent until their rupture, which may lead to detrimental ischemic events such as strokes. This is due, in part, to intraplaque hemorrhages (IPH) and the resulting inflammatory processes, which may promote carotid plaque vulnerability. Currently, the benefits of carotid endarterectomy remain unclear for asymptomatic patients. Interestingly, the completion of physical activity (PA) may have beneficial effects; however, the paucity of current data warrants robust longitudinal interventions. We therefore aim to study the effects of a 6-month longitudinal personalized home-based PA program on IPH, biological, and inflammatory markers in asymptomatic stroke patients. Methods: Eighty patients (≥ 18 years old) will be recruited for the Physical Activity and Carotid Atherosclerotic Plaque Hemorrhage (PACAPh) clinical trial from the Hospices Civils de Lyon. Patients will be eligible if they present with carotid stenosis ≥ 50% and are asymptomatic from any ischemic events for at least 6 months. Recruited patients will be randomized into either a PA or a control group, and assessed at baseline and after 6 months. At both time points, all patients will be assessed using magnetic resonance imaging to assess IPH, blood sampling to measure inflammatory markers and monocytic phenotyping, PA and sedentary behavior questionnaires, 6-min walking test, and maximal isometric quadricep contraction test. The randomized PA intervention will consist of reaching a daily walking step goal individually tailored to each patient. Steps will be collected using a wirelessly connected wristband. The number of steps completed by individuals in the PA group will be re-evaluated bimonthly to encourage walking habits. Discussion: The PACAPh study is the first of its kind representing a feasible, easily accessible therapeutic strategy for asymptomatic stroke patients. We hypothesize that the personalized home-based PA program will reduce IPH and modulate inflammatory and biological parameters in patients presenting with carotid plaques. If the results of the PACAPh study prove to be beneficial on such health parameters, the implementation of such kind of intervention in the daily treatment of these patients would be an advantageous and cost-effective practice to adopt globally. Trial registration: This study has been approved by the National Ethics Committee (IDRCB:2019-A01543-54/SI:19.06.21.40640). ClinicalTrials.gov NCT04053166

8 January 2025 in Transplant International
Verified
Journal Article
Open access
PDF file
MAMatthieu Arsicot
Matthieu Arsicot
RARaffaele Pio Ammollo
Raffaele Pio Ammollo
MBMarine Bordet
Marine Bordet
LDLeila Dehina-Khenniche
Leila Dehina-Khenniche
OTOlivier Thaunat
Olivier Thaunat
XMXavier Matillon
Xavier Matillon
The increasing age of patients with end-stage renal disease raises the issue of hostile arterial access for transplantation, with technical difficulties associated with clamping and suturing the iliac artery. Some of these patients - who theoretically represent those who would benefit the most from transplantation in terms of mortality - are contraindicated because of anatomical and medical issues. In this context, a specific endovascular device called EndoPreKiT (Endovascular Preparation for Kidney Transplantation) has been designed, enabling arterial access for transplantation via a mini-invasive procedure. It consists of a woven Dacron supported by self-expanding nitinol rings, ensuring anchorage and allowing arterial clamping. The middle part of the anterior face of the device is stentless, enabling the anastomosis directly onto the Dacron once the calcified artery wall has been removed. After a cadaveric study validating its technical feasibility, such device was successfully implanted in 10 patients considered unfit for transplantation due to severe wall calcification. Two of them have been successfully transplanted with excellent outcomes after 13 and 3 months of follow-up. EndoPreKiT device may be a significant breakthrough in transplant surgery, that could expand the horizon of eligibility to include even the most fragile patients with challenging arterial access.

20 December 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CGCharles Gibert
Charles Gibert
MWMarie Wan
Marie Wan
MAMatthieu Arsicot
Matthieu Arsicot
UHUgo Huvelle
Ugo Huvelle
TPThomas Penhoat
Thomas Penhoat
PTPauline Tirard-Collet
Pauline Tirard-Collet
This report presents an extremely rare case of fungal mycotic aneurysm due to Magnusiomyces capitatus in a 51-year-old immunocompromised woman. The diagnosis was based on multiple CT-scans and various samples positive for the pathogen identified by sequencing of the Internal Transcribed Spacer region. Long-term treatment using caspofungin for previous candidemia would have promoted the dissemination of this intrinsically echinocandin-resistant fungus, from colonization sites in the lung and rectal areas. Long-term suppressive antifungal treatment using voriconazole followed by posaconazole, combined with numerous surgical procedures, led to an improvement in the patient's disease. This case highlights the need to consider the overall microbiological history of a patient and to reassess antimicrobial therapy in case of non-improvement or relapse.

4 July 2025 in American Journal of Transplantation
Verified
Journal Article
Closed access
EMEmilien Seizilles de Mazancourt
Emilien Seizilles de Mazancourt
XMXavier Matillon
Xavier Matillon
MAMatthieu Arsicot
Matthieu Arsicot

11 October 2016 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
INIris Naudin
Iris Naudin
NSNellie Della Schiava
Nellie Della Schiava
MAMatthieu Arsicot
Matthieu Arsicot
TBTarek Boudjelit
Tarek Boudjelit
MLMeryl Favier de Lachomette
Meryl Favier de Lachomette
PLPatrick Lermusiaux
Patrick Lermusiaux